• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Intravenous Immunoglobulin Treatment for Patients with Heparin-Induced Thrombocytopenia Patients Unresponsive to Standard Treatment

August 23, 2017

Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment with significant risks of morbidity and mortality.  HIT is caused by platelet-activating antibodies against complexes of platelet factor 4 and heparin.  Although HIT patients have low levels of platelets, the risk of thrombosis is high and the use of other anticoagulants may increase the risk of bleeding.  Since standard therapies are not always successful, a recent study investigated the use of intravenous immunoglobulin G (IVIg) in three patients with HIT who did not respond to standard therapies but experienced rapid improvement with IVIg treatment.  Furthermore, platelet activation was inhibited by the constant domain (Fc) of immunoglobulin G (IgG), and it was found that certain genotypes of the platelet IgG receptor were more responsive to IVIg treatment.  Further studies are needed to evaluate the risks and benefits of IVIg treatment for HIT patients.

Reference:

  1. Padmanabhan A, Jones CG, Pechauer SM, et al.  Intravenous immunoglobulin for treatment of severe refractory heparin-induced thrombocytopenia.  CHEST (2017), doi: 10.1016/j.chest.2017.03.050.

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • Traditional Chinese Herbs Not Effective for Intracerebral Hemorrhage: A Randomized Trial

  • Transfusion Transmission of Hepatitis A Virus during a Recent Epidemic in Europe

  • Perfluoroalkyl and Polyfluoroalkyl Levels after Blood Donations

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Machine Learning Model for Estimating Perioperative Transfusion Risks

  • Blood Transfusion Strategies for Major Trauma

  • Storage Duration Affects Hematological and Metabolic Parameters in Patients with Sickle Cell Disease

  • Syphilis Infections Among US Blood Donors

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley